Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
21/04/2026
OpenAI: Companies are rapidly integrating Codex into their actual workflow in engineering and other fields.
Latest
8 m ago
Swanson gold deposit drilling confirmed the discovery of a large gold mine, with an average grade of 1.18 grams of gold per ton in the 255.04 meter section, and an average grade of 1.65 grams of gold per ton in the 136.01 meter section.
9 m ago
Zelensky: The friendship oil pipeline can be restored.
10 m ago
Federal Reserve Chair nominee Kevin Warsh begins his prepared statement for the Senate.
11 m ago
According to AI Quick News, Southwest Securities released a research report on April 21, giving Guobang Pharmaceuticals (605507.SH) a "buy" rating. The main reasons for the rating include: 1) Review: Stable growth in revenue, short-term profits under pressure, waiting for price recovery in the animal health sector; 2) Continued high growth in the animal health business, the pharmaceutical sector is undergoing a phase of adjustment; 3) Solid platform advantages, new growth engine ready to launch. (Daily Economic News)
12 m ago
According to AI Fast News, Pacific Securities published a research report on April 21 giving a "buy" rating to Meiai Technology (688376.SH). The rating reasons mainly include: 1) Significant effects of market expansion and business layout over the past 25 years, stable growth in revenue, short-term performance pressure, optimistic about the upcoming turning point; 2) Acquiring Jiexinlong to increase revenue scale, supplementing external growth with internal growth, accelerating the overall industry chain layout at home and abroad. (Daily Economic News)
See all latest
